



The Utility of ¹⁸F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma

Papiller Renal Hücreli Karsinomda Multipl Metastaz Saptanmasında ¹⁸F-FDG PET/CT'nin Yararı

✉ Melis Oflas, ✉ Duygu Has Şimşek, ✉ Serkan Kuyumcu, ✉ Murat Yılmaz Kıran, ✉ Yasemin Şanlı

Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Türkiye

Abstract

The diagnostic performance of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) for primary kidney tumors is limited. Nevertheless, ¹⁸F-FDG PET/CT is valuable for staging renal cell carcinoma (RCC) when suspected metastases coexist, as one-third of patients with RCC have distant metastases upon diagnosis. Herein, we present a 53-year-old male patient with extensive ¹⁸F-FDG-avid metastatic lesions and an ¹⁸F-FDG-avid renal mass, which later revealed RCC.

Keywords: ¹⁸F-FDG PET/CT, papillary renal cell carcinoma, metastasis, staging

Öz

Primer böbrek tümörlerinin tespitinde ¹⁸F-florodeoksiglukoz (¹⁸F-FDG) pozitron emisyon tomografisi/bilgisayarlı tomografinin (PET/CT) tanısal performansı sınırlıdır. Ancak, tanı anında renal hücreli karsinom (RCC) hastalarının üçte birinde uzak metastaz bulunduğundan dolayı metastaz şüphesi varlığında ¹⁸F-FDG PET/CT, RCC evrelemede değerli bir yöntemdir. Burada; ¹⁸F-FDG tutulumu gösteren yaygın metastazları bulunan ve ¹⁸F-FDG tutulumu gösteren renal kitleden daha sonra RCC tanısı alan 53 yaşında erkek hasta sunulmuştur.

Anahtar kelimeler: ¹⁸F-FDG PET/CT, papiller renal hücreli karsinom, metastaz, evreleme

Address for Correspondence: Melis Oflas MD, İstanbul University, İstanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Türkiye

E-mail: melis.oflas@istanbul.edu.tr **ORCID ID:** orcid.org/0000-0001-9796-3302

Received: 28.02.2024 **Accepted:** 05.06.2024 **Epub:** 17.07.2024 **Publication Date:** 07.02.2025

Cite this article as: Oflas M, Has Şimşek D, Kuyumcu S, Kıran MY, Şanlı Y. The utility of ¹⁸F-FDG PET/CT in detecting multiple metastases in papillary renal cell carcinoma. Mol Imaging Radionucl Ther. 2025;34:64-65.



Copyright© 2025 The Author. Published by Galenos Publishing House on behalf of the Turkish Society of Nuclear Medicine. This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.




Figure 1. A 53-year-old male patient with no known comorbidity was admitted to the hospital with complaints of fever, night sweats, and fatigue for the last month. Upon detecting a suspicious mass in the right kidney and lung metastases on contrast-enhanced computed tomography (CT), ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/CT was performed (A) (1,2,3,4). In the PET/CT images, an exophytic localized renal mass in the upper pole of the right kidney exhibited increased ¹⁸F-FDG uptake [maximum standardized uptake value (SUV_{max}): 5.5], which was considered suspicious for renal cell carcinoma (RCC) (B, arrows). In addition, multiple hypermetabolic parenchymal and pleural lesions in bilateral lungs (SUV_{max}: 11.9) (C, arrows), bilateral adrenal glands (SUV_{max}: 9.5) (D, arrows), liver parenchyma (SUV_{max}: 10.0) (D, arrows), peritoneum (SUV_{max}: 8.7), mesentery (SUV_{max}: 13.1), and omentum (SUV_{max}: 11.1) (E, arrows), multiple bone metastases (SUV_{max}: 12.1), and soft tissue lesions in subcutaneous tissue and muscles (SUV_{max}: 14.6) (F, arrows). All lesions that could not be distinguished on CT images were distinguished on PET/CT images. A biopsy of the renal mass revealed papillary RCC (pRCC). A few days later, after pathological diagnosis, the patient was taken to the hospital because of worsening general condition and died in the intensive care unit due to hemodynamic deterioration. pRCC has a better outcome in localized disease than clear cell RCC (ccRCC). However, metastatic pRCC is associated with higher recurrence rates and lower survival than ccRCC (5). Moreover, various studies have reported that a higher SUV_{max} or presence of metastatic disease indicates shorter survival (6,7,8). Therefore, ¹⁸F-FDG PET/CT is an efficient method for staging RCC, primarily for estimating the tumor load of metastatic disease.

Ethics

Informed Consent: Patient consent was obtained.

Authorship Contributions

Surgical and Medical Practices: M.O., M.Y.K., Concept: M.O., D.H.Ş., Y.Ş., Design: M.O., D.H.Ş., Y.Ş., Data Collection or Processing: M.O., M.Y.K., Analysis or Interpretation: M.O., S.K., Literature Search: M.O., S.K., Writing: M.O.

Conflict of Interest: No conflicts of interest were declared by the authors.

Financial Disclosure: The authors declare that this study has received no financial support.

References

- Liu Y. The Place of FDG PET/CT in Renal cell carcinoma: value and limitations. *Front Oncol.* 2016;6:201.
- Karivedu V, Jain AL, Eluvathingal TJ, Sidana A. Role of positron emission tomography imaging in metabolically active renal cell carcinoma. *Curr Urol Rep.* 2019;20:56.
- Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, Kao CH. Meta-analysis of the diagnostic performance of [¹⁸F]FDG-PET and PET/CT in renal cell carcinoma. *Cancer Imaging.* 2012;12:464-474.
- Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B. Papillary renal cell carcinoma: review. *Urol Oncol.* 2021;39:327-337.
- Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DY. Characterizing the outcomes of metastatic papillary renal cell carcinoma. *Cancer Med.* 2017;6:902-909.
- Xuan D, Wen W, Tian S, Piao M, Xu D, Liu L. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of ¹⁸F-FDG PET/CT in patients with renal carcinoma: a protocol for systematic review and meta analysis. *Medicine (Baltimore).* 2020;99:e19988.
- Pankowska V, Malkowski B, Wedrowski M, Wedrowska E, Roszkowski K. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. *Clin Exp Med.* 2019;19:143-148.
- Wu C, Cui Y, Zhao Y, Chen X, Liao X, Di L, Yin L, Liu M, Wang R. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative ¹⁸F-FDG PET/CT predicts poor prognosis of patients with clear cell renal cell carcinoma after nephrectomy. *Eur J Radiol.* 2020;131:109218.